Ionis Pharmaceuticals traded at $37.02 this Thursday June 30th, decreasing $0.54 or 1.44 percent since the previous trading session. Looking back, over the last four weeks, Ionis Pharmaceuticals lost 1.37 percent. Over the last 12 months, its price fell by 7.57 percent. Looking ahead, we forecast Ionis Pharmaceuticals to be priced at 38.19 by the end of this quarter and at 35.19 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 2,046.00 -69.00 -3.26% 6.34%
Agios Pharmaceuticals 22.17 -0.21 -0.94% -60.71%
Alnylam Pharmaceuticals 145.85 0.42 0.29% -14.08%
Arrowhead Research 35.21 0.65 1.88% -58.56%
BioCryst Pharmaceuticals 10.58 -0.23 -2.13% -34.97%
Bluebird Bio 4.14 -0.44 -9.61% -87.23%
BioMarin Pharmaceutical 82.87 -1.05 -1.25% -1.24%
Esperion Therapeutics 6.36 -0.31 -4.65% -70.24%
Exelixis 20.82 0.03 0.14% 11.70%
Halozyme Therapeutics 44.00 -1.28 -2.83% -5.09%
Intercept Pharmaceuticals 13.81 0.14 1.02% -32.54%
Moderna Inc 142.85 0.04 0.03% -39.24%
Mirati Therapeutics 67.13 -0.11 -0.16% -59.67%
Neurocrine Biosciences 97.48 -0.98 -1.00% 0.02%
Nektar Therapeutics 3.80 -0.16 -4.04% -78.31%
Novartis 80.85 -0.34 -0.42% -4.23%
Omeros 2.75 0.09 3.38% -82.44%
Pfizer 52.43 1.49 2.93% 32.53%
PTC Therapeutics 40.06 -0.34 -0.84% -8.46%
Ultragenyx Pharmaceutical 59.66 -0.58 -0.96% -36.61%
Regeneron Pharmaceuticals 591.13 -6.49 -1.09% 1.28%
Roche Holding 318.55 -1.10 -0.34% -9.02%
Sarepta Therapeutics 74.96 -2.11 -2.74% -4.23%
Vertex Pharmaceuticals 281.79 1.44 0.51% 39.36%


Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).